If your veterinarian handed you a bottle of Simplicef (cefpodoxime proxetil) for your dog's skin infection, you are holding one of the most commonly dispensed canine antibiotics in the United States — and, until recently, a brand-name-only product. As of mid-2025, a generic cefpodoxime proxetil tablet entered the US market, which is already changing what the medication costs at the pharmacy counter.

This article is a label-first monograph: what the FDA actually approved cefpodoxime for, the labeled dose and duration, the side effects shown in real openFDA pharmacovigilance data (not just label boilerplate), how it compares to the other antibiotics a vet might reach for, and — importantly for stewardship — when a once-daily third-generation cephalosporin is the right choice versus overkill for a routine skin infection.

The short answer, first

Cefpodoxime proxetil (brand name Simplicef, originally from Pharmacia & Upjohn and now owned by Zoetis, plus a generic from Felix Pharmaceuticals approved in July 2025) is a third-generation cephalosporin antibiotic FDA-approved only for the treatment of skin infections — wounds and abscesses — in dogs. It is given once daily by mouth at a label dose of 5–10 mg/kg (2.3–4.5 mg/lb) for 5–7 days (up to a maximum of 28 days for refractory cases). Its most common side effects are gastrointestinal — vomiting, diarrhea, and reduced appetite — and the main serious risk is an allergic reaction in a dog with known beta-lactam hypersensitivity.

The honest stewardship framing: cefpodoxime is genuinely useful for canine skin infections and the once-daily dosing improves owner compliance, but as a broader-spectrum third-generation cephalosporin it is not the ideal default first-line antibiotic for every simple skin infection. First-generation options (cephalexin) cover the usual canine skin pathogens with a narrower spectrum and less resistance selection. Cefpodoxime is best reserved for cases where a once-daily oral option genuinely helps compliance, where a first-generation drug is inadequate, or where culture and susceptibility specifically support it.

What does cefpodoxime treat? The FDA label

The FDA-approved label (NADA 141-232) defines a narrow, specific indication. Cefpodoxime is approved for the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of:

• Staphylococcus pseudintermedius (the primary canine skin pathogen — historically listed on the original 2004 label as S. intermedius before taxonomic reclassification)
• Staphylococcus aureus
• Streptococcus canis (group G, β-hemolytic)
• Escherichia coli
• Pasteurella multocida
• Proteus mirabilis

That pathogen list is deliberately skin-and-wound focused. Staphylococcus pseudintermedius is implicated in the large majority of canine superficial pyodermas; the gram-negative organisms on the list (E. coli, Pasteurella, Proteus) reflect bite-wound and contaminated-wound flora. Cefpodoxime is not FDA-approved for urinary tract infections, respiratory infections, or deep tissue infections in dogs in the way some other veterinary antibiotics are — though veterinarians may use it extralabel where supported by culture and susceptibility.

The label also carries the standard veterinary restriction: federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a prescription-only product.

How cefpodoxime works — and why once-daily dosing holds

Cefpodoxime is a beta-lactam antibiotic in the cephalosporin class. Like other beta-lactams, it kills bacteria by binding to penicillin-binding proteins and disrupting cell-wall synthesis; without an intact wall, the bacterium ruptures and dies. The "third-generation" label reflects when the class was developed and, more practically, its spectrum: third-generation cephalosporins like cefpodoxime retain strong gram-positive activity (including most staphylococci and streptococci) while adding improved gram-negative coverage and resistance to many bacterial beta-lactamases compared with first-generation agents such as cephalexin.

The reason cefpodoxime can be given once daily, rather than two or three times a day like cephalexin, is pharmacokinetic. The original approval studies showed that after a single oral dose, cefpodoxime plasma concentrations remain above the minimum inhibitory concentration (MIC) for the target skin pathogens for roughly a full 24 hours. Because beta-lactam killing depends on the time the drug concentration stays above the MIC (time-dependent, not concentration-dependent, activity), maintaining that coverage for 24 hours from one dose is what makes once-daily dosing clinically effective. That single property is the source of cefpodoxime's main real-world advantage: a dog whose owner can reliably give one pill a day is far more likely to complete the full course than one whose owner must give a pill every eight to twelve hours.

What is the labeled cefpodoxime dose for dogs, and how long should treatment last?

The dosage regimen from the label is:

The 5–10 mg/kg range was part of the original 2004 label: the field study used 5 mg/kg once daily, while a separate wound-model study confirmed 10 mg/kg was equally effective, so FDA approved the full range from the start. The 2014 supplement later added a flavored chewable tablet without changing the dose range. This is a dose range, not a dosing instruction — the actual dose, formulation (tablet vs. chewable), and duration for your dog depend on weight, the infection being treated, response, and your veterinarian's judgment. Always follow the prescription exactly and complete the full course unless your veterinarian tells you to stop.

The "3–4 days with no response" guidance is a useful stewardship and safety point: if a skin infection is not clearly improving within the first several days, the right move is to revisit the veterinarian for reassessment (culture, different antibiotic, or a look for an underlying cause like an atopic flare) rather than simply continuing the same drug for weeks. For dogs with recurring skin infections, the underlying allergy is usually the real driver — see our dog allergy medication guide for the atopic-dermatitis side of that equation.

What are the side effects? What openFDA actually shows

The label lists gastrointestinal signs (vomiting, diarrhea, decreased appetite) and the possibility of allergic reactions as the main adverse effects. To see how this plays out in real-world reports, we queried the openFDA Animal Adverse Event database for every report naming cefpodoxime as an active ingredient.

Table: Top reactions in cefpodoxime adverse-event reports (openFDA, queried 2026-06-25)

Across the full query, cefpodoxime was named in roughly 19,144 reaction rows, overwhelmingly in dogs (18,645, about 97%), with a small number of cat reports (354, about 1.8%) reflecting extralabel feline use.

How to read these numbers — the passive-surveillance caveat. openFDA is a passive, voluntary adverse-event reporting system. These are report counts, not incidence rates, and a report does not prove the drug caused the event. A report of "death by euthanasia" or "seizure" in a dog on cefpodoxime usually reflects a dog that was seriously ill with a severe infection (or an unrelated condition) and was on the antibiotic at the time — not a dog killed by the drug. The value of the data is in the pattern: the most common reactions cluster exactly where the label predicts (GI upset, appetite, lethargy), plus laboratory abnormalities (liver enzyme elevations) and a meaningful share of "lack of efficacy" reports that point to real-world resistance or inappropriate prescribing. This is exactly the kind of safety pattern you would expect for a widely used oral cephalosporin.

Contraindications and warnings

• Beta-lactam hypersensitivity. Cefpodoxime is contraindicated in dogs with known allergy to cefpodoxime or to other beta-lactam antibiotics (penicillins and cephalosporins). If your dog has reacted to a penicillin-class drug before, tell your veterinarian.
• Allergic reactions in people handling the drug. The label warns that cephalosporins can cause allergic reactions in sensitized individuals handling the product; avoid direct skin and mucous-membrane contact.
• Not for use in dogs with serious kidney or GI disease without veterinary oversight. Dose adjustment or monitoring may be needed.
• Pregnancy/lactation: Use only if clearly needed and directed by a veterinarian; reproductive safety data are limited.

How cefpodoxime compares to other canine skin-infection antibiotics

Cefpodoxime does not exist in isolation — it sits in a class of options for canine superficial pyoderma and wound infections. The honest comparison is what most "cefpodoxime for dogs" pages omit entirely.

Table: Cefpodoxime vs. common alternatives for canine skin infections

Two practical decisions fall out of this table.

Once-daily oral (cefpodoxime) vs. twice-daily oral (cephalexin, Clavamox). The single biggest real-world advantage of cefpodoxime is once-daily dosing, which materially improves the chance a dog actually gets every dose for the full course. Missed doses are a major driver of both treatment failure and resistance. For an owner who genuinely cannot medicate a dog twice a day, a once-daily option that is properly completed is better stewardship than a twice-daily option that is half-given. That is a legitimate reason to choose cefpodoxime.

Oral (cefpodoxime) vs. injectable (Convenia). When pilling is not feasible at all, the long-acting injectable cephalosporin cefovecin (Convenia) guarantees compliance for roughly two weeks from a single injection. The tradeoff is that you cannot "stop" a long-acting injection if an adverse reaction occurs, and the prolonged tissue exposure is a stewardship consideration. The Convenia injection guide walks through when that tradeoff is worth it.

The framing across our antibiotic coverage — including the site-wide antibiotic and anti-infective FDA adverse-event data — is consistent: match the drug's spectrum and dosing to the infection and the owner, complete the full course, and reserve the broader-spectrum options for when they are genuinely needed.

When cefpodoxime is NOT the right choice

A monograph that only lists indications is incomplete. Cefpodoxime is the wrong first choice in several common situations, and an honest guide names them.

• Uncomplicated superficial pyoderma where twice-daily dosing is feasible. For a routine first-episode staphylococcal pyoderma in a dog whose owner can medicate reliably, a first-generation cephalosporin (cephalexin) or amoxicillin-clavulanate covers the pathogen with a narrower spectrum and less resistance pressure. Cefpodoxime's broader gram-negative reach is wasted on a straightforward staph skin infection and selects for resistant organisms unnecessarily. This is the core antimicrobial-stewardship argument against using a third-generation agent as a reflex default.
• Known or suspected beta-lactam allergy. If a dog has reacted to a penicillin or another cephalosporin, cefpodoxime is contraindicated — cross-reactivity within the beta-lactam class is the central risk. A lincosamide (clindamycin) or a different drug class is the alternative.
• Documented resistant pathogen. The "lack of efficacy" reports in the openFDA data (~287 reaction rows) often reflect a pathogen that was never susceptible, or a recurrent infection driven by an unaddressed underlying cause (atopic dermatitis, ectoparasites, endocrinopathy). Continuing or escalating cefpodoxime without culture and susceptibility — or without treating the underlying driver — sets up failure and resistance.
• Deep, surgical, or abscessed infections needing drainage. Antibiotics alone do not resolve a walled-off abscess; source control (drainage, debridement) comes first. Cefpodoxime may be part of the medical management, but it is not a substitute for treating the surgical problem.
• Need for tissue or urine concentrations cefpodoxime is not labeled for. Cefpodoxime is a skin-infection label. For UTIs, deep pneumonia, osteomyelitis, or septicemia, veterinarians select drugs with the appropriate label, tissue distribution, and susceptibility data rather than defaulting to cefpodoxime.

The throughline is stewardship: the convenience of once-daily dosing is a real benefit, but it does not by itself justify a broader-spectrum drug for an infection a narrower agent can handle. The best use of cefpodoxime is a deliberate choice — when once-daily compliance genuinely matters, when the pathogen or presentation fits, or when a first-line option has failed — not a default reflex.

Giving the dose: practical notes, storage, and missed doses

A few practical points that affect whether the course actually works:

• With or without food. Cefpodoxime proxetil can be given with or without food. If your dog vomits on an empty stomach, giving the dose with a small amount of food usually resolves it.
• Complete the full course. Stopping when the skin "looks better" — typically around day 3–4 — is the most common reason a pyoderma relapses. The label's "2–3 days beyond cessation of clinical signs" exists precisely to prevent undertreating.
• Missed dose. If you realize soon after the scheduled time, give it; if it is close to the next scheduled dose, skip the missed one and resume the normal schedule — do not double up. Consistent daily timing matters more than exact clock precision.
• Storage. Store at controlled room temperature, away from moisture and direct heat, in the original container. Do not store in the bathroom where humidity fluctuates.
• Leftover medication. Never save unused cefpodoxime for a future problem or share it with another pet. A partial course left over almost always means the original course was stopped early, and reusing leftovers feeds resistance. Dispose of unused medication through a veterinary pharmacy take-back or a community drug-disposal program.

The generic-approval story (and the "first generic" correction)

A point worth getting right, because it is widely misstated: cefpodoxime proxetil has had a US generic option for more than a decade. The brand-name Simplicef tablets were originally approved under NADA 141-232 on July 22, 2004 (Pharmacia & Upjohn Co.), with a chewable-tablet supplement approved December 16, 2014 (Zoetis). The first abbreviated (generic) approval was ANADA 200-543, approved December 14, 2012 (Putney, Inc.), shown bioequivalent to Simplicef.

The approval that is genuinely new is ANADA 200-815 (Cefpodoxime Proxetil Tablets, Felix Pharmaceuticals Pvt. Ltd.), approved July 8, 2025 — a recent generic, not the first generic, distributed in the US through Butler Animal Health Supply / Covetrus. Its Freedom of Information summary demonstrates bioequivalence to the 100 mg Simplicef reference product on both AUC and Cmax, with a biowaiver for the 200 mg strength based on comparative in vitro dissolution.

What this means practically for owners:

• Generic cefpodoxime is FDA-reviewed and bioequivalent. A generic approved under an ANADA has to demonstrate bioequivalence to the brand — the same active ingredient absorbed to a comparable degree — so a properly labeled generic is therapeutically equivalent to Simplicef for the labeled indication.
• More generics = more price competition. Each additional approved generic increases the chance your pharmacy can dispense a lower-cost option, which removes a real barrier to completing a full antibiotic course.
• "Bioequivalent" does not mean identical in every respect. Excipients, flavor, and tablet appearance differ, and a small number of dogs are sensitive to specific inactive ingredients. If your dog tolerates one formulation well, there is rarely a reason to switch, but if you notice a new GI sign after a pharmacy substitution, mention it to your vet.

Frequently asked questions

Can cefpodoxime be given to cats, or is it dog-only? The FDA label is dog-only. Cefpodoxime is not approved for cats, and feline use is extralabel. (A small share of openFDA reports — about 1.8% — involve cats, reflecting extralabel prescribing.) If your cat needs an antibiotic, there are feline-labeled options; do not give a dog's cefpodoxime prescription to a cat without veterinary direction.

Is the new generic cefpodoxime (ANADA 200-815) bioequivalent to Simplicef? Yes. Felix Pharmaceuticals' generic, approved July 8, 2025, demonstrated bioequivalence to the Simplicef reference product on AUC and Cmax in dogs, the standard FDA criteria. Note that generics have existed since 2012 (Putney's ANADA 200-543); the 2025 approval adds competition rather than introducing the first generic.

What should I do if my dog vomits shortly after taking Simplicef? A single vomit shortly after a dose may be the drug irritating an empty stomach — giving future doses with a small amount of food often helps. Repeated vomiting, vomiting with lethargy or diarrhea, or any sign of an allergic reaction (facial swelling, hives, difficulty breathing) means stop and call your veterinarian promptly. Do not simply "redose" after vomiting without checking, since you cannot be sure how much was absorbed.

Why did my vet choose cefpodoxime over cephalexin or Clavamox? Common reasons: once-daily dosing fits your schedule better (improving the chance the full course is given), a prior culture-and-susceptibility result showed the pathogen is susceptible, or your dog did not tolerate or respond to a first-generation option. If you want to understand the specific reasoning for your dog, ask — "why this antibiotic, and what would make us switch?" is a fair and answerable question.

How long should my dog take cefpodoxime? Follow the prescription exactly. The label range is 5–7 days (or 2–3 days beyond the resolution of signs, up to a 28-day maximum). Stopping early — just because the skin looks better — is a major cause of relapse and resistance. Complete the full course unless your veterinarian tells you to stop.

Sources

• FDA CVM. Freedom of Information Summary, NADA 141-232 SIMPLICEF (cefpodoxime proxetil) Tablets — original approval July 22, 2004 (Pharmacia & Upjohn Co.). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/771
• FDA CVM. Freedom of Information Summary, NADA 141-232 SIMPLICEF Chewable Tablets — supplemental approval December 16, 2014 (Zoetis), 5–10 mg/kg dose range. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/772
• FDA CVM. Freedom of Information Summary, ANADA 200-543 Cefpodoxime Proxetil Tablets — first generic approval December 14, 2012 (Putney, Inc.). https://downloads.regulations.gov/FDA-2012-N-0002-0046/content.pdf
• FDA CVM. Freedom of Information Summary, ANADA 200-815 Cefpodoxime Proxetil Tablets — generic approval July 8, 2025 (Felix Pharmaceuticals Pvt. Ltd.), bioequivalent to Simplicef. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17208
• Federal Register. New Animal Drugs; Approval of New Animal Drug Applications (July 2025 approvals, including ANADA 200-815). https://www.federalregister.gov/documents/2026/02/06/2026-02331/new-animal-drugs-approval-of-new-animal-drug-applications-withdrawal-of-approval-of-new-animal-drug
• DailyMed / National Library of Medicine. SIMPLICEF (cefpodoxime proxetil) tablets label — indications, dosage, contraindications, warnings. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c935006b-bd95-4692-8cfd-722b3b072271
• FDA. Recent Animal Drug Approvals (Green Book) — confirms ANADA 200-815, July 8, 2025, Felix Pharmaceuticals. https://www.fda.gov/animal-veterinary/approved-animal-drug-products-green-book/recent-animal-drug-approvals
• openFDA Animal Adverse Event database — cefpodoxime active-ingredient adverse-event report analysis (queried 2026-06-25). https://api.fda.gov/animalandveterinary/event.json
• AAHA. Antimicrobial Stewardship Guidelines — appropriate use of cephalosporins in companion-animal practice. https://www.aaha.org/for-veterinary-professionals/aaha-guidelines/
• NCBI Bookshelf. Cephalosporins — mechanism, generations, and spectrum background. https://www.ncbi.nlm.nih.gov/books/NBK547852/
• Cherni L, et al. Comparison of the Efficacy of Cefpodoxime Proxetil and Cephalexin in the Treatment of Canine Pyoderma — Journal of Applied Research in Veterinary Medicine. https://jarvm.com/articles/Vol4Iss2/Cherni.pdf